Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Analysis of FDA approvals, delays and denials of new drug applications, 2013-2023.

Drug discovery today·2026
Same journal

Turning animal-study administration signals into drug-development intelligence.

Drug discovery today·2026
Same journal

Nano alchemy: Ionic liquids transforming metallic particles for medicine.

Drug discovery today·2026
Same journal

Reassessing galectin inhibition: Lessons for context-selective drug design and translational oncology.

Drug discovery today·2026
Same journal

Pharmacological modulation of ATF6: exploiting a stress-integrative node to overcome drug resistance.

Drug discovery today·2026
Same journal

Protein-ligand interactions by QCM: challenges and resolutions.

Drug discovery today·2026

Related Experiment Video

Updated: May 31, 2026

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

Biopharma business models in Canada.

I March-Chordà1, R M Yagüe-Perales

  • 1Facultad de Economía, Universitat de València, Avda. Tarongers s/n, 46022 Valencia, Spain. Isidre.March@uv.es

Drug Discovery Today
|June 29, 2011
PubMed
Summary

Canadian biopharma companies utilize diverse business models, including drug development, technology platforms, and incremental innovation. Analysis reveals distinct strategies across R&D, management, and innovation.

Area of Science:

  • Biopharmaceutical industry analysis
  • Business strategy in life sciences
  • Innovation management

Background:

  • Canadian biopharmaceutical sector landscape
  • Evolving business models in drug development
  • Strategic approaches in biotechnology

Purpose of the Study:

  • To investigate distinct business models and strategy paths of Canadian biopharma companies.
  • To analyze the operational, managerial, and R&D strategies within these models.
  • To provide insights into innovation strategies in the biopharma industry.

Main Methods:

  • Case study methodology
  • Analysis of seven Canadian biopharmaceutical companies
  • Categorization into three distinct business models

More Related Videos

Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI)
08:57

Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI)

Published on: August 18, 2017

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

Related Experiment Videos

Last Updated: May 31, 2026

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI)
08:57

Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI)

Published on: August 18, 2017

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

Main Results:

  • Model 1: Conventional biotech focused on new drug development and radical innovation.
  • Model 2: Technology platform development (proteomics, bioinformatics).
  • Model 3: Incremental innovation with reduced risk and timelines.

Conclusions:

  • Understanding diverse biopharma business models is crucial for strategic planning.
  • Each model presents unique opportunities and challenges in R&D, management, and innovation.
  • The study highlights varied approaches to innovation and market entry within the Canadian biopharma landscape.